[{"orgOrder":0,"company":"Prothione","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamic Acid","moa":"Glutathione peroxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Prothione","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prothione \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothione \/ Not Applicable"},{"orgOrder":0,"company":"Actor Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Glycine","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Actor Pharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.050000000000000003,"dosageForm":"Gel","sponsorNew":"Actor Pharma \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Actor Pharma \/ Cipla"}]

Find Clinical Drug Pipeline Developments & Deals for Glycine Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.

                          Brand Name : Nozohaem

                          Molecule Type : Small molecule

                          Upfront Cash : $48.6 million

                          September 05, 2023

                          Lead Product(s) : Glycine,Calcium

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Approved

                          Sponsor : Cipla

                          Deal Size : $48.6 million

                          Deal Type : Acquisition

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Data for Prothione (Glutathione) capsules, show that patients assigned treatment with the drug had a reduction in time to clinical resolution as defined by time to attain 3 consecutive negative RT-PCR tests and a statistically significant decrease in vir...

                          Brand Name : Prothione

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 15, 2022

                          Lead Product(s) : L-Glutamic Acid,L-Cysteine,Glycine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank